Foundation Future Industries says it has Pentagon research contracts to test Phantom humanoid robots and has already sent early units to Ukraine. The award and the company's ties to Eric Trump have prompted scrutiny and oversight questions.

Boston Children's says its internal ChatGPT platform helped diagnose more than 40 rare conditions while reclaiming roughly 60,000 staff hours.

A Lancet‑published head‑to‑head study led by University of Pittsburgh found MK‑6240 flags tau earlier and in more people than the standard tracer, complicating trial eligibility.

A 12‑year‑old Center Grove student is the first in Indiana to receive an FDA‑approved gene therapy at Riley, a treatment that could end her monthly transfusions.

San Antonio's Darkhive won a nearly $50 million Pentagon APFIT award to scale drone production and battlefield communications, with company leaders citing factory and hiring plans.

A Portland startup says it preserved a whole pig brain at cellular resolution and will offer the procedure to terminally ill patients in Oregon. The work raises legal and ethical questions about timing, consent and what "revival" would mean.

Google has filed with the EPA to test Wolbachia‑treated male mosquitoes in Florida, proposing 16M releases per year for two years to cut disease‑carrying populations.

UNF’s new Perry Weather Heat Lab will simulate extreme-heat conditions to test wearables, nutrition and protocols aimed at reducing preventable heat deaths among athletes, military and outdoor workers.

Objectors say Bayer’s $7.25B Roundup settlement tramples due process and favors lawyers; a May removal filing and a June 4 opt‑out deadline now cloud approval.

Chicago’s Tempus won FDA clearance to run its xT CDx test without matched normal samples, a label expansion the company says will broaden use and affect reimbursement.

The State Senate cleared SB 895, an amended $12B plan to fund research; UCSF says federal grant slowdowns have put labs and clinical trials at risk. The measure now heads to the Assembly.

Columbia researchers identify SIRT1 as a driver of treatment‑resistant neuroendocrine prostate cancer and show blocking it halts tumors in mice.

Saporo is basing its North American go‑to‑market in Columbus by partnering with Ratmir Timashev’s OH.io. Local teams will run U.S. sales and marketing while R&D stays in Europe.